scPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim Group

scPharmaceuticals (NASDAQ:SCPH) had its price objective lowered by investment analysts at Maxim Group from $20.00 to $12.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 298.01% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of scPharmaceuticals in a research report on Thursday.

scPharmaceuticals Price Performance

NASDAQ:SCPH traded down $0.03 during mid-day trading on Thursday, hitting $3.02. 216,600 shares of the company’s stock traded hands, compared to its average volume of 394,029. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The firm’s 50 day simple moving average is $3.30 and its 200 day simple moving average is $3.81. scPharmaceuticals has a 1 year low of $2.75 and a 1 year high of $5.70. The company has a market cap of $150.87 million, a PE ratio of -1.59 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. Sell-side analysts expect that scPharmaceuticals will post -1.53 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP increased its holdings in shares of scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after acquiring an additional 1,250,000 shares during the period. AIGH Capital Management LLC boosted its holdings in shares of scPharmaceuticals by 1.2% in the fourth quarter. AIGH Capital Management LLC now owns 4,174,367 shares of the company’s stock worth $14,777,000 after buying an additional 50,000 shares during the period. King Luther Capital Management Corp boosted its holdings in shares of scPharmaceuticals by 28.4% in the fourth quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock worth $10,117,000 after buying an additional 632,120 shares during the period. Suvretta Capital Management LLC acquired a new position in shares of scPharmaceuticals in the third quarter worth about $9,343,000. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after buying an additional 14,866 shares during the period. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.